With a strong deal flow and specialist expertise in life science and digital health, we’re confident that we have a unique ability to identify the best investment opportunities.
We invest alongside leading venture capital firms, family offices and other experienced investors – through our investor network Sciety Venture Partners or other collaborative arrangements where we lead the process.
Want to invest with Sciety?
We identify unlisted growth companies with strong potential to create significant value for both investors and society – and with a clear path to a future exit.
The solution meets a real need in healthcare, for patients or in research
Based on data or research with measurable outcomes
With relevant backgrounds and the capacity to build a scalable company
Long-term demand and strong conditions for growth and profitability
Ability to grow substantially with strong gross margins
Ambition to achieve 5–10x returns within 3–5 years
Our selection process is built on data, experience and deep industry insight. The goal? To find the most promising companies in life science and digital health.
Our analyst team brings operational experience from healthcare, commercial operations, finance and entrepreneurship. Two of our senior partners, with extensive experience in leadership positions in the industry, are also actively involved throughout the selection process. This gives us access to the right expertise and a strong network of specialists within each company’s specific domain.
We are selective
Each year, we review around 1,000 companies sourced through our networks, direct contacts and partners across the ecosystem. Our close relationships with serial entrepreneurs at leading universities, research parks, and within industry often provide us with early insight into compelling opportunities.
Structure, insight and experience in every analysis
We evaluate each company using a framework specifically developed for life science and digital health. The focus includes scientific evidence, market potential, team expertise and execution capability, scalability and exit opportunities. The framework is built on experience from hundreds of analyses and helps ensure we don’t miss anything critical before making an investment decision.
We verify with industry experts
We identify the key parameters for a company to succeed and validate these with professionals who have real expertise in the field, such as doctors, researchers, industry experts or other specialists. We usually work with experts from our network, but seek new contacts when it can add value.
Valuation and terms
Together with the company, we agree on valuation and terms. We use established methods, such as comparable transactions and rNPV, and weigh potential against risk. We also take the lead in structuring the shareholders’ agreement, to ensure investors’ interests are protected after the investment is completed.
We review the full picture – so you can make informed decisions
Before making an investment, we review key customer and supplier agreements, intellectual property and corporate documentation. We also conduct background checks on key individuals. Everything is compiled into a report that investors can review prior to making a decision.
“Sciety was a great partner and co-investor when we raised additional funding to one of our portfolio companies. I would strongly recommend Sciety to other venture capital firms looking for co-investors.”
Walter Stockinger
Managing Partner, Hadean Ventures
We invest in Nordic unlisted growth companies with strong positions in their respective fields. Our focus is exclusively on life science and digital health. We lead investment rounds from SEK 50 to 200 million, and we always invest our own capital in the financing rounds we lead.
Technologies that use biological material – such as antibodies, RNA or cells – to treat diseases in a more precise and targeted way.
Solutions that enable earlier and more accurate diagnoses, more effective treatment monitoring or improved clinical decisions – such as medical imaging, liquid biopsy and AI-based analysis.
Drug development in disease areas with significant unmet medical need, where current treatments are inadequate or cause serious side effects, such as in oncology or cardiovascular disease.
Tools and services that streamline research and development of new, more targeted treatments – such as reagents, sequencing technology, proteomics analysis and bioinformatics platforms.
Data-driven solutions with proven clinical benefits that improve prevention, treatment or care processes. Often based on scalable SaaS models, such as clinical decision support, remote patient monitoring and AI-based analysis.
A rigorous selection process is essential, but it’s what happens after the investment that often makes the real difference.
We choose carefully and continue to contribute as active, value-creating owners after the investment.
Sciety has a model for active ownership that includes:
Through our international life science network, we also provide strategic input to the board based on insights from experts with proven experience in the company’s field.
We are convinced that a deep understanding of the industry and active, long-term engagement are essential to building successful companies.
Our goal is to create a healthier society by investing in and developing leading companies in life science and health tech. Our results speak for themselves – over the years, we have completed numerous successful investments alongside leading specialist investors with rigorous selection processes, including venture capital firms and life science CVCs across Europe. Want to invest with us?
Investing in shares involves high risk. Read our risk policy.